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Teaser Novel drugs and novel excipients in pH-dependent ileocolonic drug delivery systems
have to be tested in animals. Which animal species are suitable and what in vivo methods
are used to verify ileocolonic drug delivery?
pH-dependent ileocolonic drug
delivery, part II: preclinical evaluation
of novel drugs and novel excipients
Annemarie Broesder1, Anne-Marijke M.A.C. Kosta2,
Herman J. Woerdenbag1, Duong N. Nguyen1,
Henderik W. Frijlink1 and Wouter L.J. Hinrichs1
1University of Groningen, Groningen Research Institute of Pharmacy, Department of Pharmaceutical Technology
and Biopharmacy, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
2University of Groningen, University Medical Center Groningen, Department of Biomedical Sciences of Cells and
Systems, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
Introduction
In part I of this review series we described in vitro and clinical methods to investigate and verify
colonic drug delivery of novel pH-dependent systems [1]. These systems utilize the sharp but
short pH peak of 7.4 (range 7.2–7.7) in the ileum for ileocolonic drug targeting. When evaluating
the ileocolonic targeting ability of a system or the therapeutic efficacy of an ileocolonic delivered
drug, it is preferable to test it directly in humans [1]. However, a novel drug and/or a novel
excipient cannot be tested in humans if no safety data from animal studies are available for the
drug or excipient used for the ileocolonic drug delivery systems [2]. Guidelines concerning safety
testing have been provided by the International Council for Harmonisation of Technical
Requirements for Pharmaceuticals for Human Use (ICH) [3]. According to these guidelines,
safety pharmacology studies have to be conducted with the final formulation in laboratory
animals if the formulation substantially alters the pharmacokinetics and/or pharmacodynamics
of the drug compared with previously tested formulations [4]. Given that ileocolonic drug
delivery systems target the drug to the lower parts of the gastrointestinal (GI) tract, both the
pharmacokinetics and pharmacodynamics of the drug will be altered, thus necessitating safety
testing with the final drug delivery system in laboratory animals. To achieve pH-dependent
ileocolonic drug delivery in animals, the animal species chosen should have a sharp distinct pH
peak in its terminal ileum. Ideally, the intestinal pH values of the animal should be comparable
with those found in humans, including the pH peak above pH 7.2 in the terminal ileum. This
would allow the use of established pH-dependent ileocolonic targeted drug delivery systems to
test novel drugs. To test novel pH-dependent excipients, the pH of the GI tract of the chosen
animal species has to be similar to that of humans to obtain ileocolonic targeting in humans.
Various species have been used for preclinical testing of new drugs or novel excipients, including
rats, mice, dogs, and rabbits. However, little emphasis has been put on the translation from
animal species to humans regarding the pH values of the GI tract.
In this review, we provide an overview of the pH values of various parts of the GI tract of
frequently used laboratory animal species and of humans. We aim to determine which animal
species, if any, could best be used to test novel drugs or novel excipients in pH-dependent
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ileocolonic drug delivery systems. Subsequently, in vivo methods
used in preclinical evaluations to investigate and verify ileocolonic
drug delivery are discussed.
Luminal pH in the gastrointestinal tract of animals
compared with humans
The pH values of the GI tract largely determine in which part of the
GI tract a drug is released from a pH-sensitive drug delivery system.
For ileocolonic drug delivery, it is important to select an animal
species that has a sharp and distinct pH peak in the terminal ileum,
as is found in the human GI tract [1]. In addition to pH, other
factors can have a role in the performance of pH-dependent
ileocolonic drug delivery systems, including intestinal length,
buffer capacity, fluid volume, motility, and transit time. These
factors have been extensively described by Hatton et al. and
Sjögren et al. [5,6], and are not further discussed in this review.
Methods to determine the pH in the gastrointestinal tract in
laboratory animals
Similar to human studies, pH values in the GI tract of animals have
been determined with aspiration via the oral route, tethered pH
electrodes, and with pH-sensitive radio telemetry capsules. In
humans, aspiration via colonoscopy has also been used to measure
the pH of the lower GI tract, but to our knowledge this method has
never been used in animals [1]. Aspiration via the oral route is
generally limited to the upper GI tract and can be used to deter-
mine the mean pH of the collected stomach or duodenal fluid ex
vivo [7,8]. If the pH of the entire GI tract during transit is to be
measured, radio telemetry capsules can be used [9–11]. A drawback
of these capsules is their large size (usually around 10  20 mm),
which limits their use to larger animals, such as dogs and pigs
(Table 1) [12–15]. With laboratory animals, ex vivo pH measure-
ments of the intestinal contents after surgical collection of samples
from different segments of the GI tract is possible [16–23]. A
drawback of this method is that only the mean pH of the collected
fluid is determined. In addition, the pH should be measured
immediately after collection to prevent possible postsampling
pH changes. This is particularly relevant for the content of the
colon, because bacterial fermentation of polysaccharides results in
the formation of acidic products which can lower the pH after
collection [24]. Another option to measure the pH in animals is to
open the GI tract by surgery and to measure the pH in situ with a
pH electrode [25–32]. With in situ pH measurements and with a
pH-sensitive radio telemetry capsule possible pH alterations after
sampling are excluded, because the pH values are measured im-
mediately.
pH values in the gastrointestinal tract of laboratory animals
The mean or median pH values found in various studies for
different segments of the GI tract (stomach, duodenum, jejunum,
ileum, cecum, and colon) of rabbits, pigs, dogs, rats, mice, guinea
pigs, and monkeys are shown as dots in Fig. 1, together with the
values for humans as reviewed in part I of this series [1]. From
publications in which both the median and mean pH values were
given, the mean values were used in this review. When multiple
pH values were reported for a certain GI tract region, for instance
the fundus and antrum of the stomach, the mean value was
calculated and used. In Fig. 1, the minimum and maximum pHvalues are indicated by bars and the mean pH values, calculated
from all different studies combined, by a vertical line. The study
size was not taken into account for the calculation of the mean. In
this overview, no differentiation is made between the fasted and
fed states, because of a lack of sufficient data on this point. To
enable comparison, the previously reported values for humans in
the fasted and fed states were also combined. Table 1 provides an
overview of the studies used, with information about the pH
measurement method and the state (fasted or fed) under which
the experiments were carried out.
Rabbits and pigs have pH values in the stomach that are within
the range of the human values (Fig. 1A,B, respectively) [16–
18,25,33]. The mean pH values of the duodenum and jejunum
in these animal species are below the minimum pH of 7.2 that is
found in the human ileum, whereas the pH values in the ileum
were higher [16–18,25,33].
A broader variation was found for the pH in the stomach of dogs
(pH 1.1–6.8; Fig. 1C) and rats (pH 3.2–6.7; Fig. 1D) [7–
11,16,18,21,23,26,28–32]. In these animals, the minimum pH of
7.2 of the human ileum is already surpassed in the duodenum and
jejunum in some of the studies. Additionally, the mean pH in the
ileum of both dogs and rats was below this minimum pH of 7.2
[7,16,18–21,23,26,28–30].
Mice have a higher pH in the stomach but a lower pH in the
small and large intestine compared with humans (Fig. 1E)
[16,22,23,28]. The minimum pH of 7.2 found in the ileum of
humans was not reached in any part of the murine GI tract.
In guinea pigs, the pH values of the GI tract are higher than
those of humans (Fig. 1F). The minimum pH of 7.2 was reached in
the duodenum in some of the studies and was above pH 7.2 in the
jejunum in all studies until the cecum, where the pH drops until
6.7 [16,25].
In monkeys, the mean pH in the stomach was higher than in
humans (Fig. 1G) [16,34]. The pH increases to pH 6.0 in the ileum
and then drops to 5.0 in the cecum and colon [16]. However, care
must be exercised to draw definite conclusions from these data
because the pH values of the small intestine and colon are based on
only one study.
Selection of an appropriate animal species
For the preclinical evaluation of novel drugs or novel excipients
applied in pH-dependent systems, we found that no particular
animal species is commonly used (Table 2). It is remarkable that in
most studies no information is given about the rationale behind
the chosen animal species. In view of the working principle of pH-
sensitive ileocolonic targeted drug delivery systems, a pH peak in
the terminal ileum of the animal should be considered as the most
important factor. Furthermore, pH values similar to the human GI
tract would be ideal, because in that case an existing and well-
validated pH-dependent system can be used to obtain ileocolonic
drug delivery in the chosen animal species or novel pH-dependent
excipients can be evaluated.
The pH profile of the GI tract of monkeys, mice, and guinea pigs
differs from that in humans and no distinctive pH peak has been
found in the terminal ileum. Therefore, these laboratory animal
species should be considered unsuitable for testing novel drugs in
pH-dependent ileocolonic drug delivery systems (Fig. 1). Dogs and

































Overview of studies investigating the pH values of the GI tract in laboratory animals and in healthy human individuals
Animal Segment gastrointestinal tract Method Refs
Species Breed Stomach Duodenum Jejunum Ileum Cecum Colon pH measurement Fasted/fed
Monkey Cynomolgus X X X X X X Ex vivoa Fed ad libitum [16]
X BravoTM capsuleb Fasted and fed [34]
Pig From farms X X X X X X Ex vivoa Fed ad libitum [16]
Crossbreed of large white and Landrace X X X X X X In situa Fed ad libitum [25]
X X X X X X Ex vivoa Fed ad libitum [18]
Large white, Landrace, and Essex X X X X X X Ex vivoa Fasted for 1 hour [17]
Mouse Balb/c X X X X X X Ex vivoa Fasted and fed [23]
House X X X X X In situa N/Ae [27]
X X Ex vivoa Fed ad libitum; high and low fiber diet [22]
White X Ex vivoa Fed ad libitum [16]
Rat Albino Norwegian X X X X X In situa Fasted and fed ad libitum [28]
Porton-Wistar X X X X In situa Fasted, fed ad libitum and fed standardized [29]
X X X X In situa Fed [26]
White X X X X X X Ex vivoa Fed ad libitum [16]
Wistar X X X X X X Ex vivoa Fasted and fed [23]
X X X X X X Ex vivoa Fed ad libitum [18]
X X X X In situa Fasted [30]
Rabbit New Zealand Whites X X X X X X Ex vivoa Fed ad libitum [16]
X X X X X X Ex vivoa Fed ad libitum [18]
X X X X X X In situa Fed ad libitum [25]
X X N/Ae Fed ad libitum [33]
Guinea pig N/Ae X X X X X X Ex vivoa Fed ad libitum [16]
Dunkin-Hartley White X X X X X X In situa Fed ad libitum [25]
Dog Beagle X Heidelberg capsule Fasted [9]
X Aspiration Fasted [8]
X In situa Fasted [31]
X BravoTM capsule Fed big or small meal before capsule ingestion [10]
X BravoTM capsule Fasted, fed standard meal and fed slurry meal [11]
X In situa Fed [32]
From domestic households X X X X X X Ex vivoa Fed ad libitum [16]
Labrador X X Aspiration Fasted [7]
X Ex vivoa Fasted and fed [20]
Mixed X Ex vivoa Fasted [19]
N/Ae X X X X X X Ex vivoc Fasted [21]
Human X X X X X Telemetry capsule Fasted; food when capsule left stomach [105]


















































TABLE 1 (Continued )
Animal Segment gastrointestinal tract Method Refs
Species Breed Stomach Duodenum Jejunum Ileum Cecum Colon pH measurement Fasted/fed
X X X In situa Fasted [38]
X X X X X Telemetry capsule Fasted; food allowed when capsule left stomach [40]
X X X X Intellicap1 capsule Fasted; food allowed 4 h after ingestion [107]
X X Heidelberg capsule Fasted and fed [108]
X X Aspiration Fasted [109]
X X Aspiration Fasted [110]
X X X SmartPill Fed; FDA standard breakfast [111,112]
X X X SmartPill Fasted; after 4.5 h standardized lunch [111]
X X X X X Telemetry capsule Fed; food allowed after ingestion of capsule [36]
X X X IntelliCap1 Fasted; food 3, 6 and 10 h after ingestion [92]
X X SmartPill Fed; gastric-emptying meal [113]
X Heidelberg capsule Fasted; food 3 h after capsule left stomach [9]
X In situa Fasted and fed standard meal [114]
X Aspiration Fasted [115]
X In situa Fasted [116]
X Aspiration Fasted [117]
X In situa Fasted and fed [118]
X Heidelberg capsule Fed; standardized breakfast [119]
X In situa Fasted and fed [120]
X In situa Fasted and fed [121]
X X X X X Telemetry capsule Fasted; food allowed when capsule left stomach [122]
X X X X Telemetry capsule Fed; normal diet [123]
X X X X Telemetry capsule Fasted; food allowed when capsule left stomach [37]
X X Aspiration Fasted [124]
X X Heidelberg capsule Fed [125]
X Aspiration Fasted, fed and fed fat-enriched meal [126]
X BravoTM capsuled Fed; standardized meal twice daily [127]
X Aspiration Fasted [128]
X Aspiration Fasted [129]
X Aspiration Fasted and fed [130]
X X X Telemetry capsule Fasted; food allowed when capsule left stomach [131]
X X X SmartPill Fasted; food allowed 6 h after ingestion [132]
X X SmartPill Fasted; standardized meal when capsule left stomach [133]
X X SmartPill Fed; test meal, after 6 h normal diet [39]
aMeasured with a pH electrode.
b Capsule attached to stomach.
c Colorimetric and with a pH electrode.
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Drug Discovery Today 
FIGURE 1
Luminal gastrointestinal (GI) pH values of laboratory animals (dark-green, orange, or red bars) and healthy human individuals (light-green bars). The different pH
values of the GI tract of the (a) rabbit [16,18,25,33], (b) pig [16–18,25], (c) dog [7–11,16,19–21,31,32], (d) rat [16,18,23,26,28–30], (e) mouse [16,22,23,27],
(f) guinea pig [16,25], and (g) monkey [16,34] are given against the values in healthy human individuals [9,36–40,92,105–133]. The GI pH ranges are indicated by
bars, the vertical line in the bars indicates the mean pH. The mean or median pH values of the different segments of the GI tract found in the different studies are
indicated by the black dots. Only one study was found for pH values for the duodenum, ileum, cecum, and colon in the monkey and, therefore, only this value is
given as a dot and a vertical line. Table 1 in the main text details the studies that were used to obtain the minimum, maximum, and mean pH values for the


























segments of their GI tract are generally comparable to those in
humans, including a pH peak in the terminal ileum (Fig. 1).
However, their mean pH value in the ileum is below the minimum
value in humans. Furthermore, the pH values in the GI tract
substantially varied among the different studies. Therefore, it is
advised to check the inter- and intraindividual variation in pH
values of the GI tract of the dogs or rats used in the experiments.
Given the relatively broad range of gastric pH values in dogs, it is
recommended to pretreat the animals with a 0.1 M HCl-KCl solu-
tion, via an orogastric tube, to lower the pH of the stomach [35].
Rabbits and pigs have pH values comparable to those in humans,
including the pH peak in the ileum above pH 7.2 (Fig. 1). The pH
values in the different segments of the GI tract showed relatively
little variation between the different studies. For rabbits, the mean
pH in the jejunum was slightly higher (7.1) than in humans, which
might result in premature drug release. However, the rabbit is the
only animal species having a distinct pH peak in the ileum, with
the minimum pH above 7.0. For pigs, the minimum pH found was
6.6, which is considerably lower. In four out of five pig studies, a
pH in the ileum above 7.0 was found, whereas this was the case for
all three rabbit studies. Thus, when using pigs, it is advised to check
the pH values of the GI tract of the individual animals to verify
whether they are comparable to those of humans and constant
over time.
Overall, the rabbit appears to be the most reliable species for
testing novel drugs with established pH-dependent ileocolonic drug
delivery systems because of the low pH variability and the distinct
pH peak above 7.0 in the ileum. When the inter- and intraindividual
variations in pH values of the different regions of the GI tract are
checked for rabbits, ileocolonic drug targeting might be proved with
even more certainty. In cases where the pH values of the GI tract for
individual pigs or dogs are comparable to those in humans, are
constant over time, and if the pH threshold of the system is reached,
these animal species might be good alternatives to the rabbit,
because larger drug delivery systems can be administered. When
multiple animal species are found to have appropriate pH values in
the GI tract, pilot studies could be performed to determine which
species is most optimal to obtain ileocolonic drug delivery with the
chosen drug delivery system. To test the therapeutic effect of a novel
drug in preclinical studies (Table 2), diseased rather than healthy
animals should be used. However, a diseased state could change the
pH values in the GI tract in animals, even though it was found that
colonic diseases did not negatively affect the pH values in humans
[1,36–40]. However, despite these results, it is still recommended to
check the pH values of the GI tract of diseased animals, because the
effects of a colonic disease on the intestinal pH have not yet been
described for animals.
It should also be possible to mimic a specific disease in the
chosen animal species to enable measurement of the therapeutic
effect of a novel drug. In the literature, several colonic disease
models have been described for the rabbit (Table 3), which,
according to our review, is the most reliable animal species to test
novel drugs in a pH-dependent ileocolonic drug delivery system.
Another important aspect to be taken into consideration is that
the pharmacokinetics and/or pharmacodynamics of a drug might
be different in an animal compared with humans. Thus, an animal
species should be selected with care, to avoid false negative or false
positive results.In vivo methods to investigate or verify ileocolonic
targeting in laboratory animals
Before performing in vivo studies, the pH dependency of a chosen
delivery system should be verified in a challenging in vitro disso-
lution test. The dissolution test should mimic the pH profile and
preferably the buffer capacity, buffer type, and ionic strength of
the human GI tract, as described in part I of this series [1]. To draw
conclusions from the in vivo efficacy data of a novel drug or the
targeting ability of a drug delivery system containing a novel
pH-dependent excipient, it is important to verify ileocolonic drug
delivery in the chosen animal species. Different methods have
been used to verify ileocolonic drug delivery in animals. These
methods include investigation of tissue samples and utilization of
imaging techniques, such as X-ray imaging (radiography and
fluoroscopy), g-scintigraphy, fluorescence microscopy, and near-
infrared (NIR) fluoroscopy. Furthermore, drug plasma concentra-
tions and therapeutic effects have been used. These methods are
discussed in more detail in the following sections.
Harvesting tissue samples
After sacrificing an animal, tissue samples can be collected in
which the drug concentration is determined or in which the drug
delivery system and/or the drug is detected with micro- or macro-
scopic techniques. Different sections of the GI tract can be re-
moved from the animal, such as the stomach, small intestine,
cecum, and large intestine. Four different methods have been
developed to analyze harvested tissue samples (Table 4). All of
these methods are applicable for drugs that are absorbed into the
systemic circulation, but, under certain conditions, three of them
can be used for drugs that are not absorbed from the GI tract.
In the first method (i) the intestinal content is immediately
washed away. Subsequently, the drug, if present, is extracted from
the tissue by an appropriate method and quantified [41–45]. With
this method, drug release is indicated by the presence of drug in
the extract because only released drug can be absorbed by the
intestinal tissue. In the second method (ii), the washing step is
omitted and the luminal fluid is included, next to the intestinal
tissue, in the extraction procedure [46,47]. To draw conclusions
from the drug content data, it is important to validate the extrac-
tion procedure and to determine whether the drug is completely
extracted from the drug delivery system or not at all. If the drug is
indeed completely extracted (iia) from the dosage form, drug
release is indicated by incomplete recovery because, in that case,
part of the drug has been absorbed into the systemic circulation
[47]. If the drug is not extracted from the dosage form (iib), then
presence of the drug in the extract is indicative of drug release [46].
In the third method (iii), only the drug content in the luminal
content is measured while the tissue itself is not used [48]. For this
method, it is also important to know whether the drug is complete-
ly extracted from the drug delivery system or not at all. If the drug
is completely extracted (iiia), incomplete recovery indicates drug
release. If the drug is not extracted (iiib), the presence of the drug
in the extract indicates drug release. In the fourth method (iv), the
drug delivery system is retrieved from the luminal content and
only the drug content in the delivery system itself is determined
[49]. In this method incomplete recovery indicates drug release.
In three of the different approaches, the location of release of

































Overview of pH targeted ileocolonic drug delivery systems tested in laboratory animals
Animal Drug delivery system In vivo test Refs




(M) and/or coating (C)
Drug/marker Read out Colon arrival
determined with





Based on practical considerations Yes Eudragit FS 30 D (C) Meloxicam Plasma samples Plasma concentrations
and colon arrival time
from literature
[78]






Pharmacokinetics No Eudragit FS 30 D Lovastatin Plasma samples N/A [134]







GI tract comparable to human Yes Eudragit P-4135 F (C);
Eudragit L (C); Eudragit S
(C)




Rat N/A No Eudragit S (C) Mesalazine and/or
curcumin
Colitis severity N/A [135]
N/A No N-succinyl chitosan/Zn2+
(M)
Mesalazine and/or zinc Colitis severity Colitis severity and in
vitro release
[99]
N/A No Acrylic acid and butyl
meth-acrylate polymers
(M)
Aceclofenac Colitis severity N/A [136]
N/A No Eudragit S (M) Celecoxib and/or
curcumin
Colitis severity N/A [137]
N/A No Poly(starch/acrylic acid)
(M)
Rutin Colitis severity Colitis severity and in
vitro release
[100]
N/A No Eudragit P-4135 F (M) Tacrolimus Colitis severity, plasma
samples
N/A [138]
N/A No Eudragit P-4135 F (M) Tacrolimus Colitis severity Colitis severity and in
vitro release
[101]
N/A No Eudragit S (M) Aceclofenac Paw edema severity N/A [139]
N/A No Eudragit P-4135 F (M) Calcitonin; carboxy-
fluorescein
Plasma samples Plasma concentrations
and colon arrival time
from literature
[79]
N/A No P(LE-IA-MEG) (M) Dexamethasone Plasma samples Plasma samples and in
vitro release
[81]
N/A No Eudragit S (C); Eudragit L
(C); Eudragit RS100 (C)
Insulin Plasma samples N/A [140]
N/A No Eudragit L100-55 (M);
Eudragit L (M); Eudragit S
(M)




















































TABLE 2 (Continued )
Animal Drug delivery system In vivo test Refs




(M) and/or coating (C)
Drug/marker Read out Colon arrival
determined with
N/A No Eudragit S (C) Budesonide Tissue sections
harvested
Tissue concentrations [41]
N/A No Eudragit S (C); alginate
(M)



























and visual observation of
lower part of small
intestine
[51]














Disease model available No Eudragit S/PLGAb (M);
Eudragit S (M)







N/A Yes Eudragit S (M); Eudragit L
(M); Eudragit L100-55 (M)
Prednisolone Plasma samples Not determined because
of failure of system (pH
threshold not reached in
rat)
[143]





N/A No Eudragit S (C) Curcumin and
cyclosporine
Colitis severity Colitis severity and in
vitro release
[103]
N/A No Eudragit S (M) Tacrolimus Colitis severity In vitro release [145]












































































TABLE 2 (Continued )
Animal Drug delivery system In vivo test Refs




(M) and/or coating (C)
Drug/marker Read out Colon arrival
determined with
Mouse N/A No Eudragit S/Eudragit L (C) Sulfasalazine Paw edema severity N/A [146]
N/A No P(CE-MAA-MEG) (M) Mesalazine Colitis severity Colitis severity [102]
Disease model available No Eudragit S/PLGA (M) Curcumin Colitis severity N/A [147]
N/A No Eudragit P-4135 F (M) Tacrolimus Colitis severity N/A [148]














Disease model available No Eudragit FS 30 D/PLGAb
(M)













Disease model available No Eudragit S (M) Curcumin Colitis severity; plasma
samples; fecal matter
Fecal concentrations [48]
Mouse and rabbit Disease model available (mouse)
and N/A (rabbit)




Rabbit N/A No Eudragit S/Ethyl cellulose
(C)
Metronidazole Plasma samples Plasma samples and
colon arrival time from
literature
[80]
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TABLE 3
Examples of colonic disease models in rabbits
Disease Disease induction Refs




Moist heat, stress, and low-dose laxatives [154]





Diluted acetic acid intrarectally [157]




Inoculation with Eimeria magna oocytes
intragastrically
[162]
Degraded carrageenan orally [163]
Lipopolysaccharide intrarectally after 1%
formalin enema
[164]
Inoculation with Crohn’s tissue homogenates
intraileally
[165]
Immune complex intravenously in
combination with dilute formalin intrarectally
[166]
Inoculation with Bacteroides vulgatus intra-
appendiceal
[167]














identified (iib, iiib, and iv) (Table 4). One option is to retrieve the
drug delivery system itself (iv) and to measure the drug content in
the system, in which incomplete recovery indicates drug release.
In the other approaches (iib and iiib), it is important that the drug
is not extracted from the drug delivery system and that the luminal
content is included in the assay either with or without the tissue.
Drug release is then indicated by the presence of drug in the
extract.
All methods described above measure drug content. Next to this
approach, it is possible to detect the drug delivery system (e.g.,
microspheres or tablets) in harvested tissue samples visually or
with a light microscope. In case of dissolving or eroding systems,
these methods allow for the conformation of drug release from the
disappearance of the drug delivery system [50–54]. When the drug
delivery system is still present, drug release cannot be ruled out.
More information is obtained when release can be visualized by
fluorescence microscopy or NIR fluorescence microscopy, when a
marker is included in the delivery system. For fluorescence micros-
copy, fluorescein or coumarin-6 have been used as markers and for
NIR fluorescence imaging, 1,10-dioctadecyl-3,3,30,30-tetramethy-
lindotricarbocyanine iodide (DiR), has been used [45,51,55,56].
Furthermore, cellular uptake of the marker/drug can be used to
verify release [45,46,57,58].TABLE 4
Overview of methods used to analyze harvested tissue samples
Method Drug extracted 
Tissue Luminal content Delivery syste
i X 
iia X X X 
iib X X 
iiia X X 
iiib X 
iv X 
a The total drug content is not retrieved.When tissue sections are harvested, multiple animals are re-
quired. The consequence of this is that individual animals with
variable GI transit times are compared, which makes interpreta-
tion of the data less reliable when the data are pooled. Moreover,
the exact location of drug release cannot easily be determined,
especially for multiparticulate formulations, such as microspheres,
because they spread throughout the GI tract. Additionally, many
animals have to be sacrificed to obtain data at sufficient time
points. Furthermore, possible degradation or metabolization
and/or transfer of the drug to the plasma have to be taken into
account. The advantage of harvesting tissue samples is that it is
possible to assess whether the drug has reached the colon. If the
drug does not reach the colon, no drug would be measured or
visually detected in the colonic tissue and/or luminal content.
However, if no drug is measured or visually detected in the colonic
tissue, it cannot be excluded with certainty that the drug has not
reached the colon. More reliable conclusions can be drawn when
plasma samples are taken at the same time points as the tissue
samples, on the condition that the drug is immediately absorbed
into the systemic circulation after release. The presence of drug in
plasma indicates drug release and the presence in tissue sections
might indicate the site of release.
Non-invasive imaging techniques
An attractive alternative to harvesting tissue samples, also in the
light of the 3Rs (reduction, refinement, and replacement) for animal
experiments [59], is the use of non-invasive imaging techniques.
Most frequently used are radiography and fluoroscopy, followed by
g-scintigraphy and NIR fluorescence imaging [60–71].
Ionizing radiation, X-rays, are used in radiography and fluoros-
copy to capture the images while in g-scintigraphy the marker in
the dosage form emits ionizing g-radiation [72–74]. To visualize
the dosage form in radiography or fluoroscopy, a contrast agent
(e.g., barium sulfate) has to be integrated in the drug delivery
system [73,74]. For radiography, fluoroscopy, and g-scintigraphy,
the cumulative ionizing radiation exposure has to be considered in
the study design to ensure humane treatment of the animals. This
is especially the case when animals are not sacrificed after the
study, because radiation can cause long-term effects [75]. With NIR
fluorescence imaging, no ionizing radiation is used and instead a
fluorescent agent (e.g., DiR) is used as a marker compound [60,74].
The downside of NIR fluorescence imaging is that it suffers from a
low resolution because of attenuation, scattering, and dispersion
of the emitted light when it passes through tissues [60,74]. With
all imaging techniques, the animals have to be restrained or
brought under anesthesia to prevent blurred images, which causesDrug release indicated by Applicable for drugs




Presence of drug X
Incomplete recovery
Presence of drug X
Incomplete recovery X
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IEWdiscomfort to the animal [75]. Radiography, fluoroscopy, and
g-scintigraphy are also used in clinical studies. The advantages
and disadvantages of these methods were described in more detail
in part I of this series [1].
Based on the evaluation of published animal studies in which
non-invasive imaging techniques are applied, we suggest aspects
that could be improved. Generally, only images were taken from
one angle, generating a 2D image of the abdomen [60–71,73].
Reasons for taking only one image angle could be, for instance,
reduction of radiation exposure, animal welfare, or practical con-
siderations. Images from only one angle might lead to misinter-
pretation of disintegration and/or erosion of the drug delivery
system or of the exact location of the drug delivery system in the
GI tract because the depth cannot be determined. When the
location of the different segments of the GI tract is determined
with, for instance, a barium sulfate meal study in radiography or
fluoroscopy studies, interpretation of the images is more straight-
forward [61,62,66,67,73,76]. Interpretation of images is more
problematic in animal studies than in clinical trials because, in
humans, the location of the large intestine is fixed in the body and
the outline of the large intestine becomes visible when the marker
is released [1]. In addition, the projection of the 2D images (e.g.,
dorsoventral) is often not given and the printed image quality and
size is sometimes not optimal [60–62,64–70], which complicates
interpretation of these images by the readers. Furthermore, image
exposure and animal positioning could be improved, which would
simplify interpretation of the images [60–64,66–69,71]. When
these factors are not optimal and when only images from one
angle are used, one should be reluctant with statements about
colon targeting, because structures in the abdomen overlap and
the exact 3D position cannot be determined with certainty.
Imaging techniques, when performed correctly, provide useful
information about the position of a drug delivery system in the GI
tract. However, these techniques do not provide information
about the drug release from a system and, therefore, do not
automatically give information about the ileocolonic targeting
ability. This shortcoming can be overcome by combining imaging
techniques with measuring plasma concentrations, especially
when the drug and an imaging marker are combined in the same
drug delivery system [60,62,67,71]. However, this is only valid for
drugs that are absorbed over the entire GI tract.
Plasma samples
Drug and/or drug metabolite concentrations in plasma samples
have been frequently used as a proof for ileocolonic drug delivery
in animal studies (Table 2) [52,77–81]. However, plasma concen-
trations generally do not provide enough information to confirm
ileocolonic drug delivery. An option is to compare the pharmaco-
kinetic data obtained from the plasma curve to the colon arrival
time, to determine whether the observed lag time of the system is
sufficiently long to warrant targeting to the colon [62,77–80].
Kennedy et al. developed a method to measure the colonic arrival
time, also called mouth-to-cecal transit time, in humans, using
sulfasalazine [82], which has been validated by others [83]. This
method is based on the fact that sulfasalazine is poorly absorbed by
the GI tract but is converted by bacteria in the colon into sulfa-
pyridine, which is subsequently absorbed [84,85]. Several research-
ers have used this method to circumvent interindividual variation1384 www.drugdiscoverytoday.comin colon arrival times [52,86]. It is also possible to circumvent the
intraindividual variation in colon arrival time by combining sul-
fasalazine with a release marker (e.g., theophylline) in the drug
delivery system [1,87]. In this method, theophylline is used as a
marker for drug release, since it is absorbed over the entire GI tract.
If there is no difference in plasma arrival time between theophyl-
line and sulfapyridine, it indicates that the formulation released its
contents into the colon. A downside of this method is that it only
gives an answer to the question whether the drug delivery system
releases its contents into the colon, but does not provide informa-
tion as to the exact location in the colon. To determine the exact
location of drug release, imaging techniques can be used in
combination with the theophylline-sulfasalazine method. Fur-
thermore, the pharmacokinetics and/or pharmacodynamics of
the investigated drug might be influenced by either sulfasalazine
or the release marker (in case the drug itself cannot be used as a
release marker). In addition, sulfasalazine is degraded into not
only sulfapyridine, but also mesalazine, which is a pharmacologi-
cally active compound used in the treatment of inflammatory
bowel disease [82,88]. This should be taken into account if the
compounds are combined into one drug delivery system.
Breath and urine samples
In addition to using plasma samples to determine the orocecal
transit time, it is possible to use breath samples [89,90]. This
method utilizes 13C-urea (a stable isotope), which is metabolized
by bacteria into 13CO2 that is subsequently exhaled. In human
volunteers, this method in combination with measuring 13C-urea
and 15N-urea (an internal standard) in urine has been used to verify
colonic drug delivery [1,91–93]. This principle could also be used
in laboratory animals. Collection of urine in animals is possible by
using a metabolic cage or by catheterization [94]. However, the use
of metabolic cages generates a stressful environment for animals
because of individual housing and the wire mesh floors, which can
influence the therapeutic effect of a drug or exacerbate disease
symptoms [94,95]. The latter stressor can be prevented by using
hydrophobic sand for urine collection [96], but individual housing
would remain an issue. In addition, catherization is problematic
because, among other issues, the catheter can be removed by the
animal, and inserting the catheter is a stressor on its own [97]. The
collection of breath samples is also problematic because of stress
caused by handling or individual housing in a breath-test system
[94,98]. The non-invasive character of the method makes it an
ideal method to verify colonic drug delivery in humans [1];
however, because of the implications of urine and breath collec-
tion in laboratory animals, we do not recommend this method for
animal studies.
Therapeutic effect
The last method, abundantly used to evaluate ileocolonic drug
delivery systems in laboratory animals, is to determine a thera-
peutic effect (Table 2) [99–103]. However, the therapeutic effect as
such does not directly answer the question whether the drug is in
fact targeted to, and released into, the ileocolonic region. Thera-
peutic proteins or peptides given orally in an ileocolonic drug
delivery system are an exception because they will be degraded in
the upper GI tract. Therefore, they can only elicit a therapeutic
effect if they are released in the colon [104]. In other cases, a














therapeutic effect should not be used as such to verify ileocolonic
drug targeting, but should be used in combination with imaging
techniques and plasma sampling to verify successful targeting.
When the theophylline–sulfasalazine method is used or urine is
collected with a metabolic cage, the influence on therapeutic
effects of the drug under investigation should first be taken into
account before conducting the experiments.
Overall, the determination of the therapeutic effect is valuable,
because it can answer the questions whether the drug delivery
system can improve clinical symptoms and whether it is superior
to nontargeted drug delivery systems.
Concluding remarks
For testing novel drugs for ileocolonic delivery and/or for pH-
dependent ileocolonic drug delivery systems containing novel
excipients, animals have to be used. To obtain ileocolonic drug
delivery, a sharp distinct pH peak in the terminal ileum is crucial,
thus a similar pH to humans is not essential. However, if the pH
profile of the GI tract in animals is similar to that of humans,
established ileocolonic drug delivery systems can be used to test
novel drugs. When novel pH-dependent excipients have to be
tested, a pH profile similar to that in humans is a prerequisite to
obtain ileocolonic drug delivery in humans. In this respect, the
rabbit is the most appropriate animal species compared with other
frequently used laboratory animals, because their GI pH values are
most similar to those of the human GI tract. However, not only the
pH values of the GI tract, but also the desired disease model and
the size of the delivery system have to be taken into account. If the
rabbit cannot be used, then the pig, rat, and dog might be suitable
alternatives, on the condition that the pH values of individualanimals are verified first. To properly draw conclusions from the
obtained efficacy data, ileocolonic drug delivery must be verified.
The different methods used for this verification all have specific
advantages and limitations, thus the optimal method should be
determined for each study. Non-invasive imaging techniques in
combination with plasma sampling can be used if the therapeutic
effect of a novel drug is investigated. When a novel excipient in the
drug delivery system itself is subject of investigation, the theoph-
ylline-sulfasalazine method is an elegant way to verify colonic
drug delivery.
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85 Schrôder, H. et al. (1973) Metabolism of salicylazosulfapyridine in healthy subjects
and in patients with ulcerative colitis; Effects of colectomy and of phenobarbital.
Clin. Pharmacol. Ther. 14, 802–809
86 Takaya, T. et al. (1995) Development of a colon delivery capsule and the
pharmacological activity of recombinant human granulocyte colony-stimulating
factor (rhG-CSF) in Beagle dogs. J. Pharm. Pharmacol. 47, 474–478
87 Ishibashi, T. et al. (1999) Evaluation of colonic absorbability of drugs in dogs using
a novel colon-targeted delivery capsule (CTDC). J. Control. Release 59, 361–376
88 Khan, A.K.A. et al. (1977) An experiment to determine the active therapeutic
moiety of sulphasalazine. Lancet 310, 892–895
89 Uchida, M. and Yoshida, K. (2009) Non-invasive method for evaluation of
gastrocecal transit time by using a breath test in conscious rats. J. Pharmacol. Sci.
110, 227–230














90 Uchida, M. and Yoshida-Iwasawa, K. (2012) Simultaneous measurement of
gastric emptying and gastrocecal transit times in conscious rats using a breath
test after ingestion of acetic acid and lactose- ureide. J. Smooth Muscle Res. 48, 105–
114
91 Maurer, M.J.M. et al. (2013) Isotope-labelled urea to test colon drug delivery
devices in vivo: principles, calculations and interpretations. Isotopes Environ. Health
Stud. 49, 473–491
92 Maurer, J.M. et al. (2015) Gastrointestinal pH and transit time profiling in healthy
volunteers using the IntelliCap system confirms ileocolonic release of ColoPulse
tablets. PLoS One 10, e0129076
93 Maurer, J.M. et al. (2013) ColoPulse tablets perform comparably in healthy
volunteers and Crohn’s patients and show no influence of food and time of food
intake on bioavailability. J. Control. Release 172, 618–624
94 van Zutphen, L.F. et al. eds (2001) Principles of Laboratory Animal Science, Elsevier
95 Whittaker, A.L. et al. (2016) Effects of metabolic cage housing on rat behavior
and performance in the social interaction test. J. Appl. Anim. Welf. Sci. 19, 363–
374
96 Hoffman, J.F. et al. (2018) Hydrophobic sand versus metabolic cages: a comparison
of urine collection methods for rats (Rattus norvegicus). J. Am. Assoc. Lab. Anim.
Sci. 57, 51–57
97 Horst, P.-J. et al. (1988) A new method for collecting urine directly from the ureter
in conscious unrestrained rats. Kidney Blood Press. Res. 11, 325–331
98 Uchida, M. et al. (2005) Simple and noninvasive breath test using 13C-acetic acid
to evaluate gastric emptying in conscious rats and its validation by
metoclopramide. J. Pharmacol. Sci. 98, 388–395
99 Duan, H. et al. (2017) Co-delivery of zinc and 5-aminosalicylic acid from alginate/
N-succinyl-chitosan blend microspheres for synergistic therapy of colitis. Int. J.
Pharm. 516, 214–224
100 Abdel Ghaffar, A.M. et al. (2016) Radiation synthesis of poly(starch/acrylic acid)
pH sensitive hydrogel for rutin controlled release. Int. J. Biol. Macromol. 92, 957–
964
101 Lamprecht, A. et al. (2005) FK506 microparticles mitigate experimental colitis with
minor renal calcineurin suppression. Pharm. Res. 22, 193–199
102 Bai, X.Y. et al. (2016) Novel pH-sensitive hydrogels for 5-aminosalicylic acid colon
targeting delivery: in vivo study with ulcerative colitis targeting therapy in mice.
Drug Deliv. 23, 1926–1932
103 Desai, N. and Momin, M. (2020) Colon targeted bioadhesive pellets of curcumin
and cyclosporine for improved management of inflammatory bowel disease. Drug
Deliv. Transl. Res. 34, 893–900
104 Aguirre, T.A.S. et al. (2016) Current status of selected oral peptide technologies in
advanced preclinical development and in clinical trials. Adv. Drug Deliv. Rev. 106,
223–241
105 Fallingborg, J. et al. (1998) Small intestinal transit time and intraluminal pH in
ileocecal resected patients with Crohn’s disease. Dig. Dis. Sci. 43, 702–705
106 Ibekwe, V.C. et al. (2008) Interplay between intestinal pH, transit time and feed
status on the in vivo performance of pH responsive ileocolonic release systems.
Pharm. Res. 25, 1828–1835
107 Koziolek, M. et al. (2015) Investigation of pH and temperature profiles in the GI
tract of fasted human subjects using the Intellicap1 system. J. Pharm. Sci. 104,
2855–2863
108 Dressman, J.B. et al. (1990) Upper gastrointestinal (GI) pH in young, healthy men
and women. Pharm. Res. 7, 756–761
109 Kalantzi, L. et al. (2006) Characterization of the human upper gastrointestinal
contents under conditions simulating bioavailability/bioequivalence studies.
Pharm. Res. 23, 165–176
110 Psachoulias, D. et al. (2011) Precipitation in and supersaturation of contents of the
upper small intestine after administration of two weak bases to fasted adults.
Pharm. Res. 28, 3145–3158
111 Schneider, F. et al. (2016) Resolving the physiological conditions in bioavailability
and bioequivalence studies: Comparison of fasted and fed state. Eur. J. Pharm.
Biopharm. 108, 214–219
112 Koziolek, M. et al. (2015) Intragastric pH and pressure profiles after intake of the
high-caloric, high-fat meal as used for food effect studies. J. Control. Release 220,
71–78
113 Maqbool, S. et al. (2009) Wireless capsule motility: Comparison of the SmartPill1
GI monitoring system with scintigraphy for measuring whole gut transit. Dig. Dis.
Sci. 54, 2167–2174
114 Hila, A. et al. (2006) Postprandial stomach contents have multiple acid layers. J.
Clin. Gastroenterol. 40, 612–617
115 Pedersen, P.B. et al. (2013) Characterization of fasted human gastric fluid for
relevant rheological parameters and gastric lipase activities. Eur. J. Pharm.
Biopharm. 85, 958–965116 Savarino, V. et al. (1988) 24-hour study of intragastric acidity in duodenal ulcer
patients and normal subjects using continuous intraluminal pH-metry. Dig. Dis.
Sci. 33, 1077–1080
117 Pounder, R.E. et al. (1976) Effect of cimetidine on 24-hour intragastric acidity in
normal subjects. Gut 17, 133–138
118 Fimmel, C.J. et al. (1985) Long-term ambulatory gastric pH monitoring: Validation
of a new method and effect of H2-antagonists. Gastroenterology 88, 1842–1851
119 Mojaverian, P. et al. (1988) Effects of gender, posture, and age on gastric residence
time of an indigestible solid: pharmaceutical considerations. Pharm. Res. 5, 639–
644
120 Simonian, H.P. et al. (2005) Regional postprandial differences in pH within the
stomach and gastroesophageal junction. Dig. Dis. Sci. 50, 2276–2285
121 Vo, L. et al. (2005) The effect of rabeprazole on regional gastric acidity and the
postprandial cardia/gastro-oesophageal junction acid layer in normal subjects: a
randomized, double-blind, placebo-controlled study. Aliment. Pharmacol. Ther. 21
1321–1230
122 Fallingborg, J. et al. (1989) pH-Profile and regional transit times of the normal gut
measured by a radiotelemetry device. Aliment. Pharmacol. Ther. 3, 605–614
123 Bown, R.L. et al. (1974) Effects of lactulose and other laxatives on ileal and colonic
pH as measured by a radiotelemetry device. Gut 15, 999–1004
124 Perez de la Cruz Moreno, M. et al. (2006) Characterization of fasted-state human
intestinal fluids collected from duodenum and jejunum. J. Pharm. Pharmacol. 58,
1079–1089
125 Mojaverian, P. et al. (1989) Gastrointestinal transit of a solid indigestible capsule
as measured by radiotelemetry and dual gamma scintigraphy. Pharm. Res. 6, 719–
724
126 Clarysse, S. et al. (2009) Postprandial evolution in composition and characteristics
of human duodenal fluids in different nutritional states. J. Pharm. Sci. 98, 1177–
1192
127 Bratten, J. and Jones, M.P. (2009) Prolonged recording of duodenal acid exposure
in patients with functional dyspepsia and controls using a radiotelemetry pH
monitoring system. J. Clin. Gastroenterol. 43, 527–533
128 Annaert, P. et al. (2010) Ex vivo permeability experiments in excised rat
intestinal tissue and in vitro solubility measurements in aspirated human
intestinal fluids support age-dependent oral drug absorption. Eur. J. Pharm. Sci. 39,
15–22
129 Brouwers, J. et al. (2006) Intraluminal drug and formulation behavior and
integration in in vitro permeability estimation: A case study with amprenavir. J.
Pharm. Sci. 95, 372–383
130 Riethorst, D. et al. (2016) Characterization of human duodenal fluids in fasted and
fed state conditions. J. Pharm. Sci. 105, 673–681
131 Evans, D.F. et al. (1988) Measurement of gastrointestinal pH profiles in normal
ambulant human subjects. Gut 29, 1035–1041
132 Mikolajczyk, A.E. et al. (2015) Assessment of tandem measurements of pH
and total gut transit time in healthy volunteers. Clin. Transl. Gastroenterol. 6,
e100
133 Zarate, N. et al. (2010) Accurate localization of a fall in pH within the ileocecal
region: validation using a dual-scintigraphic technique. Am. J. Physiol. Liver
Physiol. 299, G1276–G1286
134 Hubert, S. et al. (2018) Development of a modified-release formulation of
lovastatin targeted to intestinal methanogens implicated in irritable bowel
syndrome with constipation. J. Pharm. Sci. 107, 662–671
135 Duan, H. et al. (2016) Mucoadhesive microparticulates based on polysaccharide for
target dual drug delivery of 5-aminosalicylic acid and curcumin to inflamed colon.
Colloids Surf. B Biointerfaces 145, 510–519
136 Arya, A. et al. (2017) Design and evaluation of acrylate polymeric carriers
for fabrication of pH-sensitive microparticles. Drug. Dev. Ind. Pharm. 43, 305–
318
137 Gugulothu, D. et al. (2014) pH-sensitive nanoparticles of curcumin–celecoxib
combination: Evaluating drug synergy in ulcerative colitis model. J. Pharm. Sci.
103, 687–696
138 Lamprecht, A. et al. (2005) A pH-sensitive microsphere system for the colon
delivery of tacrolimus containing nanoparticles. J. Control. Release 104, 337–
346
139 Sanka, K. et al. (2015) A pH-triggered delayed-release chronotherapeutic drug
delivery system of aceclofenac for effective management of early morning
symptoms of rheumatoid arthritis. J. Microencapsul. 32, 794–803
140 Touitou, E. and Rubinstein, A. (1986) Targeted enteral delivery of insulin to rats.
Int. J. Pharm. 30, 95–99
141 Bazan, L. et al. (2016) Comparative pharmaceutical study on colon targeted
micro-particles of celecoxib: in-vitro–in-vivo evaluation. Drug Deliv. 23, 3339–
3349www.drugdiscoverytoday.com 1387










IEW142 Zhang, S. et al. (2016) Development of microbeads of chicken yolk antibodies
against Clostridium difficile toxin A for colonic-specific delivery. Drug Deliv. 23,
1940–1947
143 Kendall, R.A. et al. (2009) Fabrication and in vivo evaluation of highly pH-
responsive acrylic microparticles for targeted gastrointestinal delivery. Eur. J.
Pharm. Sci. 37, 284–290
144 Pandey, S. et al. (2018) Multiple response optimisation of processing and
formulation parameters of pH sensitive sustained release pellets of capecitabine for
targeting colon. J. Microencapsul. 35, 259–271
145 Ali, A.S. et al. (2020) Colon-targeted therapy of tacrolimus (FK506) in the treatment
of experimentally induced colitis. Pharmacology Published online January 5, 2020
https://www.karger.com/Article/Abstract/505101
146 Kankala, R.K. et al. (2015) Multi-laminated metal hydroxide nanocontainers for
oral-specific delivery for bioavailability improvement and treatment of
inflammatory paw edema in mice. J. Colloid Interface Sci. 458, 217–228
147 Xiao, B. et al. (2015) Oral administration of pH-sensitive curcumin-loaded
microparticles for ulcerative colitis therapy. Colloids Surf. B Biointerfaces. 135, 379–
385
148 Meissner, Y. et al. (2006) Nanoparticles in inflammatory bowel disease: Particle
targeting versus pH-sensitive delivery. Int. J. Pharm. 316, 138–143
149 Pellequer, Y. et al. (2007) Epithelial heparin delivery via microspheres mitigates
experimental colitis in mice. J. Pharmacol. Exp. Ther. 321, 726–733
150 Agostino, D. et al. (1959) Capsule implantation: method for establishing simulated
colon carcinoma in rats. Proc. Soc. Exp. Biol. Med. 100, 717–718
151 Whiteley, H.W. (1967) Preoperative radiation therapy in simulated cancer of the
colon in rabbits. Dis. Colon Rectum 10, 100–102
152 Sugimura, T. (1976) Experimental tumors in digestive organs. Gastroenterol. Jpn.
11, 265–266
153 Ward, J.M. (1975) Dose response to a single injection of azoxymethane in rats. Vet.
Pathol. 12, 165–177
154 Yang, Q.Q. et al. (2017) Differential expression of microRNA related to irritable
bowel syndrome in a rabbit model. J. Dig. Dis. 18, 330–3421388 www.drugdiscoverytoday.com155 Tanaka, T. et al. (2012) Effects of TAK-480, a novel tachykinin NK2-receptor
antagonist, on visceral hypersensitivity in rabbits and ricinoleic acid-induced
defecation in guinea pigs. J. Pharmacol. Sci. 120, 15–25
156 Tanaka, T. et al. (2012) Establishment and validation of a rabbit model for in vivo
pharmacodynamic screening of tachykinin NK2 antagonists. J. Pharmacol. Sci. 118,
487–495
157 Fretland, D.J. et al. (1990) Effect of the leukotriene B4 receptor antagonist SC-
41930 on colonic inflammation in rat, guinea pig and rabbit. J. Pharmacol. Exp.
Ther. 255, 572–576
158 Morris, G.P. et al. (1989) Hapten-induced model of chronic inflammation and
ulceration in the rat colon. Gastroenterology 96, 795–803
159 Anthony, D. et al. (1995) The characterization of a rabbit model of inflammatory
bowel disease. Int. J. Exp. Pathol. 76, 215–224
160 Rabin, B.S. (1980) Animal model: immunologic model of inflammatory bowel
disease. Am. J. Pathol. 99, 253–256
161 Rabin, B.S. and Rogers, S.J. (1978) A cell-mediated immune model of inflammatory
bowel disease in the rabbit. Gastroenterology 75, 29–33
162 Sundaram, U. and West, A.B. (1997) Effect of chronic inflammation on electrolyte
transport in rabbit ileal villus and crypt cells. Am. J. Physiol. Liver Physiol. 272,
G732–G741
163 Watt, J. and Marcus, R. (1970) Ulcerative colitis in rabbits fed degraded
carrageenan. J. Pharm. Pharmacol. 22, 130–131
164 Hotta, T. et al. (1986) Lipopolysaccharide-induced colitis in rabbits. Res. Exp. Med.
186, 61–69
165 Cave, D.R. et al. (1973) Further animal evidence of a transmissible agent in Crohn’s
disease. Lancet 302, 1120–1122
166 Hodgson, H.J.F. et al. (1978) Immune-complex mediated colitis in rabbits. An
experimental model. Gut 19, 225–232
167 Shanmugam, M. et al. (2005) Bacterial-induced inflammation in germ-free rabbit
appendix. Inflamm. Bowel Dis. 11, 992–1926
168 Leonardi, I. et al. (2015) Oral administration of dextran sodium sulphate induces a
cecum-localized colitis in rabbits. Int. J. Exp. Pathol. 96, 151–162
